1. Home
  2. BCE vs BIIB Comparison

BCE vs BIIB Comparison

Compare BCE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BCE Inc.

BCE

BCE Inc.

HOLD

Current Price

$25.62

Market Cap

24.3B

Sector

N/A

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.76

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCE
BIIB
Founded
1880
1978
Country
Canada
United States
Employees
40390
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3B
27.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
BCE
BIIB
Price
$25.62
$183.76
Analyst Decision
Hold
Buy
Analyst Count
2
27
Target Price
$29.50
$194.72
AVG Volume (30 Days)
2.6M
827.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$3.80
N/A
Revenue Next Year
$1.33
N/A
P/E Ratio
$5.19
$21.03
Revenue Growth
N/A
2.22
52 Week Low
$20.28
$110.04
52 Week High
$26.52
$202.41

Technical Indicators

Market Signals
Indicator
BCE
BIIB
Relative Strength Index (RSI) 46.38 47.42
Support Level $22.59 $181.24
Resistance Level $26.02 $186.17
Average True Range (ATR) 0.44 5.30
MACD -0.10 -1.11
Stochastic Oscillator 2.55 19.48

Price Performance

Historical Comparison
BCE
BIIB

About BCE BCE Inc.

BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to HBO Max and Starz.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: